相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS)
Amer M. Zeidan et al.
AMERICAN JOURNAL OF MEDICINE (2013)
Myelodysplastic syndromes: What do hospitalists need to know?
Amer M. Zeidan et al.
JOURNAL OF HOSPITAL MEDICINE (2013)
Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma
Amer Zeidan et al.
LEUKEMIA & LYMPHOMA (2013)
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines
Amy J. Davidoff et al.
LEUKEMIA RESEARCH (2013)
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Amer M. Zeidan et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mhairi Mitchell et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Epidemiology of Myelodysplastic Syndromes
Xiaomei Ma
AMERICAN JOURNAL OF MEDICINE (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
H. Joachim Deeg et al.
BLOOD (2012)
Allogeneic hematopoietic cell transplantation for MDS: For whom, when and how?
Boglarka Gyurkocza et al.
BLOOD REVIEWS (2012)
MDS: Refining existing therapy through improved biologic insights
Jordan Schecter et al.
BLOOD REVIEWS (2012)
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
Rami S. Komrokji et al.
CANCER (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited
Andres Jerez et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndromes
Uwe Platzbecker
SEMINARS IN HEMATOLOGY (2012)
T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
Elaine M. Sloand et al.
BLOOD (2011)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Raphael Itzykson et al.
BLOOD (2011)
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
Mikkael A. Sekeres et al.
BLOOD (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elias Campo et al.
BLOOD (2011)
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: Critical for Cure?
Theo de Witte
Clinical Lymphoma Myeloma & Leukemia (2011)
The 5q-Syndrome: Biology and Treatment
Eric Padron et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2011)
Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care-SAKK 33/99
Jakob R. Passweg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Myelodysplastic Syndromes
Peter L. Greenberg et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Updates in Cytogenetics and Molecular Markers in MDS
Ramon V. Tiu et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2011)
Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD
U. Gergis et al.
BONE MARROW TRANSPLANTATION (2010)
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study
Bart L. Scott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
Elaine M. Sloand et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-Risk Myelodysplastic Syndromes: Chemotherapy, Transplantation, and Beyond
Usama Gergis et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2010)
Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4+ subset and oligoclonal in the CD8+ subset
Claudio Fozza et al.
EXPERIMENTAL HEMATOLOGY (2009)
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance
A. John Barrett et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes
Matteo Giovanni Della Porta et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF:: the GFM experience
Sophie Park et al.
BLOOD (2008)
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome:: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Emilio Paolo Alessandrino et al.
BLOOD (2008)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias
Giuseppe Leone et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
Elaine M. Sloand et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:: evidence from a core dataset of 2124 patients
Detlef Haase et al.
BLOOD (2007)
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation
Stephanie J. Lee et al.
BLOOD (2007)
Immunomodulatory therapy for myelodysplastic syndromes
Lubomir Sokol et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7
Bjoern Rueter et al.
BLOOD (2007)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Andrea Pellagatti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
Pearlie K. Epling-Burnette et al.
BLOOD (2007)
Myelodysplastic syndromes - Incidence and survival in the United States
Xiaomei Ma et al.
CANCER (2007)
CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins
Elaine M. Sloand et al.
BLOOD (2007)
Myelodysplastic syndromes: the complexity of stem-cell diseases
Seth J. Corey et al.
NATURE REVIEWS CANCER (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome
Marcin W. Wlodarski et al.
BLOOD (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
H Kantarjian et al.
CANCER (2006)
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis
BL Scott et al.
LEUKEMIA (2006)
Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes
A Matsuda et al.
BLOOD (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes
D Campioni et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes
P Musto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing
R Stasi et al.
ANNALS OF ONCOLOGY (2004)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
E Hellström-Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors
R Tehranchi et al.
BLOOD (2003)
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes
D Bowen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia;: two parallel studies adjusted for various prognostic factors
M Oosterveld et al.
LEUKEMIA (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis
YE Claessens et al.
BLOOD (2002)
Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases
EH Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
